A participant who died during a trial of AstraZeneca Plc’s Covid-19 vaccine in Brazil hadn’t received the company’s shot, according to a person familiar with the matter.
The person asked not to be identified because the information isn’t public.
Brazil’s health authority Anvisa said it had been informed on Monday of the study volunteer’s death and had received a partial report from an international committee assessing the trial’s safety. That committee suggested the trial should continue, Anvisa said in a statement.
AstraZeneca, which is developing the vaccine with the University of Oxford, said it can’t comment on individual cases because of confidentiality and clinical trial rules. Oxford has no concerns about the safety of the vaccine trial after an independent and careful review, and Brazil’s regulators have recommended that it continue, university communications head Stephen Rouse said in statement.
Market Data 
Markets 
AI
